GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Shiller PE Ratio

CNBX (CNBX Pharmaceuticals) Shiller PE Ratio : (As of Apr. 12, 2025)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CNBX Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for CNBX Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Shiller PE Ratio Chart

CNBX Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CNBX Pharmaceuticals Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CNBX Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, CNBX Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Shiller PE Ratio falls into.


;
;

CNBX Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CNBX Pharmaceuticals's E10 for the quarter that ended in Nov. 2024 is calculated as:

For example, CNBX Pharmaceuticals's adjusted earnings per share data for the three months ended in Nov. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Nov. 2024 (Change)*Current CPI (Nov. 2024)
=-0.001/133.1099*133.1099
=-0.001

Current CPI (Nov. 2024) = 133.1099.

CNBX Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201502 -0.120 99.032 -0.161
201505 -0.240 100.333 -0.318
201508 -0.840 100.548 -1.112
201511 -0.120 100.135 -0.160
201602 -0.120 100.040 -0.160
201605 -0.030 101.355 -0.039
201608 0.120 101.617 0.157
201611 -0.120 101.829 -0.157
201702 -0.120 102.779 -0.155
201705 -0.240 103.256 -0.309
201708 -0.960 103.587 -1.234
201711 -0.480 104.072 -0.614
201802 -1.680 105.052 -2.129
201805 -0.840 106.148 -1.053
201808 -0.720 106.383 -0.901
201811 -0.600 106.338 -0.751
201902 7.800 106.649 9.735
201905 -4.800 108.048 -5.913
201908 0.120 108.245 0.148
201911 -4.560 108.519 -5.593
202002 -0.600 109.139 -0.732
202005 -6.000 108.175 -7.383
202008 -6.000 109.662 -7.283
202011 -0.600 109.793 -0.727
202102 -0.480 110.968 -0.576
202105 -1.170 113.576 -1.371
202108 -0.190 115.421 -0.219
202111 -1.200 117.269 -1.362
202202 -1.010 119.703 -1.123
202205 -0.550 123.323 -0.594
202208 -0.940 124.958 -1.001
202211 -0.330 125.607 -0.350
202302 -1.330 126.928 -1.395
202305 -0.020 128.314 -0.021
202308 -0.025 129.538 -0.026
202311 -0.006 129.548 -0.006
202402 -0.010 130.930 -0.010
202405 -0.004 132.509 -0.004
202408 0.000 132.816 0.000
202411 -0.001 133.110 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CNBX Pharmaceuticals  (OTCPK:CNBX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CNBX Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary